our solutions:
Phage-based precision antimicrobials:
fast and effective
At Kinzbio, we create phage-based treatments and prevention solutions to tackle
antibiotic-resistant infections. Our platform allows us to deliver (semi) personalized, pharmaceutical-grade therapies in just 5-15 days,
based on the specific bacteria causing the patient’s infection.
We also develop solutions to prevent infections in hospitals and ICUs.
We combine patents, proprietary databases, biobanks and AI-driven software to identify and optimize phages for medical and industrial applications, giving us a strong advantage in precision antimicrobials.
what sets us apart?
Our approach is:
​
-
Personalized: Tailored to the specific needs of each patient or process.
-
Adaptable: Capable of adjusting to emerging challenges.​
-
Fast: Delivering solutions in just 5–15 days.
-
Environmentally friendly and
health-conscious: naturally safe for the environment and highly specific in targeting only harmful bacteria. -
Highly specific: Targeting only the bacteria responsible for the infection, without affecting beneficial microbes.
OUR PROGRESS SO FAR
successful treatments
Successfully treated the first patients in Uruguay, achieving complete bacterial eradication after phage therapy for various medical conditions such as ventilator-associated pneumonia, urinary tract infections, and prosthetic joint infections.
New opportunities
support
Our technology and strategy have received validation and support from esteemed international incubators and accelerators like INCATE and Eretz.Bio (Albert Einstein Hospital), which are aiding in our next steps.
Regulatory development
We established a specific regulatory framework in collaboration with the local Ministry of Health, aligned with international regulations being developed in Europe and the U.S.
We’re exploring new markets in Brasil, Europe and Colombia, where a team member is actively assessing business and commercialization prospects.
unleashing the potential of
phages together
Kinzbio fosters collaborations and partnerships with pharma leaders, clinical organizations, academic labs and funding agencies to help the company to accelerate the development of its phage platform and pipeline.
Kinzbio has an open communication channel with and is always seeking to hear from industry partners and funding institutions interested in joining efforts to keep developing applications based on the biology of phages.
BE IN
TOUCH
Please fill your contact details below:
ANtimicrobial
resistance is one
of the major global
health issues that
humanity is facing
every year millions
of lives are lost and
billions are spent in
prevention and
treatment of AMR
phages are natural
bacterial killers
that can be used to
combat AMR pathogens
Kinzbio created an innovative
technology platform
designed to develop phage-based
precision antimicrobials for
the treatment and prevention
of infections caused by
top-priority AMR pathogens.
